NCT05253495 (RADICAL) is a Phase 2 clinical trial of DOC Group B in Non-hodgkin Lymphoma, sponsored by New York Medical College.

Who is sponsoring NCT05253495?

NCT05253495 is sponsored by New York Medical College.

What drugs are being tested in NCT05253495?

Interventions in NCT05253495: DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B, DOC Group C, MAD CPR 1 and 2, Pv-R CYVE 1 and 2, Pv-R CYVE-MTX 1 and 2, MAD CP, Pv-Cytarabine/etoposide, AD CP, Bv-AVD-R 1 and 2: COHORT IIa, Bv-NVD-R, Cycle 1-2, Bv-NVD-R, Cycle 1-4 SER, Bv-AVD-R, Bv-NVD-R, Cycle 1-4 RER, Bv-NAVD-R, Cycle 1-2, Involved Site Radiation Therapy.

What condition does NCT05253495 study?

NCT05253495 studies Non-hodgkin Lymphoma, Hodgkin Lymphoma.

Is NCT05253495 still recruiting?

NCT05253495 is currently recruiting now. Last updated 13 June 2025.

Last reviewed 2025-06-13 · How we verify

NCT05253495: RADICAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

Recruiting now Phase 2 Last updated 13 June 2025

What this trial tests

Phase 2 trial testing DOC Group B in Non-hodgkin Lymphoma in 80 participants. Currently enrolling.

Timeline

1 February 2022

Primary endpoint
31 December 2027

30 June 2028

Quick facts

Lead sponsor	New York Medical College
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 February 2022
Primary completion	31 December 2027
Estimated completion	30 June 2028
Sites	3 locations across United States

Drugs / interventions tested

DOC Group B — full drug profile →
Pv-COMRAD 1 and 2 Group B
Pv-R-CYM 1 and 2 Group B
DOC Group C — full drug profile →
MAD CPR 1 and 2 — full drug profile →
Pv-R CYVE 1 and 2 — full drug profile →
Pv-R CYVE-MTX 1 and 2
MAD CP
Pv-Cytarabine/etoposide
AD CP — full drug profile →
Bv-AVD-R 1 and 2: COHORT IIa
Bv-NVD-R, Cycle 1-2
Bv-NVD-R, Cycle 1-4 SER
Bv-AVD-R
Bv-NVD-R, Cycle 1-4 RER
Bv-NAVD-R, Cycle 1-2
Involved Site Radiation Therapy

Conditions studied

Non-hodgkin Lymphoma — all drugs for Non-hodgkin Lymphoma →
Hodgkin Lymphoma — all drugs for Hodgkin Lymphoma →

Sponsor

New York Medical College

Who can join

Adults 3 to 39, any sex, with Non-hodgkin Lymphoma or Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies.
Shang J, Hu S, Wang X. · · 2024 · cited 13× · PMID 38396050 · DOI 10.1186/s40164-024-00481-y
Mature B-cell lymphomas in adolescents and young adults.
El-Mallawany NK, Giulino-Roth L, Burke JM, Hermiston M, et al · · 2023 · cited 3× · PMID 38024628 · DOI 10.1002/jha2.783
Applying biotechnology to overcome cancer drug resistance and improve public health outcomes.
Adjei FA, Frempong BK, Afriyie A. · · 2026 · PMID 41638902 · DOI 10.24171/j.phrp.2025.0336

Verify or expand the search:

Other recruiting trials for Non-hodgkin Lymphoma

Currently open trials in the same condition.

NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06299462 — PTCy and ATG for MSD and MUD Transplants · Phase 1, PHASE2 · recruiting
NCT06393335 — Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory C · EARLY_PHASE1 · recruiting
NCT06323525 — TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma · Phase 1, PHASE2 · recruiting

Other New York Medical College trials

Trials by the same sponsor.

NCT06617286 — CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma · Phase 1, PHASE2 · not yet recruiting
NCT07225972 — Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC · Phase 3 · not yet recruiting
NCT07013565 — Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL · Phase 2 · active not recruiting
NCT05987124 — Defibrotide Dose-escalation for SOS Post-HSCT · Phase 2 · recruiting
NCT05564598 — CMV CTLs in Neonates With CMV Infection · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05253495 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by New York Medical College
Last refreshed: 13 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05253495.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing